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Overview of the STAT5 signaling node in mammary 
epithelial cells
Signal transducer and activator of transcription (STAT) 
5A and STAT5B are members of a well-known group of 
transcription factors [1-3]. STATs were ﬁ  rst identiﬁ  ed as 
members of a non-tyrosine kinase-containing cytokine 
receptor-activated signaling pathway [4]. Th   ere are seven 
identiﬁ  ed components of the STAT transcription factor 
family: STAT 1 to 4, 5A, 5B, and 6. STAT5A and STAT5B
are closely related family members thought to be a result 
of gene duplication [1,5]. During normal mammary gland 
development, STAT5A plays the more prominent role 
[6-10], whereas both STAT5A and STAT5B have been 
des  cribed as contributing to breast cancer pathophysiology 
[11-17]. After interactions of cytokines, hormones, and 
growth factors with their respective cell surface recep-
tors, STATs are activated, primarily by phosphorylation 
at tyrosine residues, and then dimerize and translocate to 
the nucleus. Once in the nucleus, STATs can initiate gene 
transcription [2]. Th  e activity of STAT proteins can be 
inﬂ   uenced by serine phosphorylation [18], regulated 
dephosphorylation [19], and interactions with cellular 
proteins, including adhesion and basement membrane 
molecules. In mammary epithelial cells, the STAT5A/B 
(STAT5) pathway modulates three diﬀ  erent cellular out-
comes: diﬀ  erentiation, survival, and proliferation (Figure 1). 
Th  e two STAT5 proteins, STAT5A and STAT5B, can 
homodimerize and heterodimerize. Th  e relative impact 
of STAT5 on the three diﬀ  erent cellular outcomes varies 
in normal as compared with malignant mammary 
epithelial cells as well as between diﬀ   erent types of 
normal and malignant mammary epithelial cells.
In mammary epithelial cells, STAT5 can be activated 
through a few diﬀ  erent and sometimes interacting signal-
ing pathways (Figure  2). Many of the pathways that 
mediate normal development and lactational diﬀ  erentia-
tion (Figure 3) also regulate STAT5 activation in breast 
cancer cells (Figure 4) but with a few distinctions. Janus 
kinase (JAK) 2, a tyrosine kinase, is a key signaling node 
for STAT5 activation in both normal and malignant 
mammary epithelial cells [17,20,21]. In normal mammary 
epithelial cells, this is predominantly mediated through 
prolactin (PRL) acting through the PRL receptor (PRLR) 
upstream of JAK2/STAT5 [22-25]. Interestingly, in breast 
cancer cells, JAK1 activation through a PRLR-JAK2 inter-
action can enhance STAT5 signaling [26]. Human 
cellular-Src (c-Src) is a second key signaling node for 
STAT5 activa  tion in normal and malignant mammary 
epithelial cells. Loss of c-Src interrupts STAT5 activation 
during preg  nancy, and in malignant cells c-Src has been 
shown to mediate STAT5 activation downstream of 
estrogen/estrogen receptor-alpha (ERα) and epidermal 
growth factor (EGF) signaling and to contribute to 
activation through the PRL/PRLR/JAK2 pathway 
[4,16,27-29]. One example of the impact of these 
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activation of STAT5 by estrogen and EGF [28]. When 
activated by estrogen in breast cancer cells, STAT5 
requires c-Src and EGF, but if the EGF receptor (EGFR)/
c-Src pathway is hyperactivated, the responsive  ness to 
changes in the estrogen pathway activation is altered and 
this can contribute to the development of endo  crine 
therapy resistance. A second example lies behind the 
deleterious eﬀ  ect of recombinant human erythro  poietin 
(rHuEPO) on the sensitivity to trastuza  mab in breast 
cancer cells [30,31]. Trastuzamab is a monoclonal 
antibody that targets the human EGFR 2/Neu receptor, 
an important growth stimulus for a subset of breast 
cancers. Resistance to trastuzumab occurs when rHuEPO 
stimulates JAK2, leading to the activation of both c-Src 
and STAT5. In normal mammary epithelial cells, growth 
hormone (GH) acting through the GH receptor and JAK2 
can activate STAT5 [32]. Th  e EGFR and ErbB4 – or v-
erb-b2 erythroblastic leukemia viral oncogene homolog 
4, neuro/glioblastoma-derived onco  gene homolog (avian) 
– are reported to directly associate with and activate 
STAT5 in mammary epithelial cells [33-35]. Th  e IGF 
pathway plays an important role in STAT5 activation in 
mammary epithelial cells, and signaling through the IGF 
receptor can be processed through the JAK/STAT 
pathway [36].
Activity of the STAT5 pathway in mammary epithelial 
cells is also regulated at the level of STAT5A and STAT5B 
gene expression. Expression levels can be modiﬁ  ed by 
changes in the activity of estrogen and progesterone 
signal  ing pathways [37-39] and by either EGF or IGF 
stimulation [40,41]. E74-like factor 5 (ets domain trans-
cription factor) (ELF5) appears to modulate both expres-
sion levels and activation of STAT5, perhaps through 
changes in expression levels of suppressor of cytokine 
signaling (SOCS) family members [42].
Protein-protein interactions between STAT5 and other 
cellular proteins are able to modify STAT5 action. One 
class of protein-protein interactions in mammary 
epithelial cells is between STAT5 and the nuclear 
hormone receptors expressed in these cells, including 
ERα [43-45], progesterone receptor (PR) [46], and gluco-
corticoid receptor [7,47-50]. Other cellular proteins that 
have been shown to impact STAT5 activity include PI 
3-kinase enhancer A (PIKE-A) [51], serine/threonine 
protein kinase Akt (AKT) [52], p21-activated kinase 1 
Figure 1. STAT5 infl  uences diff  erentiation, survival, and proliferation through alterations in cellular gene expression. After activation 
by tyrosine phosphorylation (P), STAT5A and STAT5B form homodimers and heterodimers that move into the nucleus, where they can act as 
transcription factors to infl  uence gene expression. STAT5, signal transducer and activator of transcription 5.
STAT5
P
STAT5
P
GENE EXPRESSION
STAT5$
P
STAT5$
P
STAT5%
P
P
STAT5$
P
STAT5%
P
STAT5%
Survival Differentiation Proliferation
Furth et al. Breast Cancer Research 2011, 13:220 
http://breast-cancer-research.com/content/13/5/220
Page 2 of 14(Pak1) [18], the transcription factor proto-oncogene v-Myb 
myeloblastosis viral oncogene homolog (avian) (c-Myb) 
[53], breast tumor kinase (Brk) [54], and caveolin [55].
STAT5 has been shown to have a role in controlling the 
activity of factors that can contribute to its own activa-
tion. STAT5, particularly STAT5B, has been shown to 
regulate IGF levels in mammary tissue and liver 
[12,56-58]. A feedback loop through SOCS molecules has 
been suggested as a mechanism to regulate the IGF/
STAT5 signaling axis [36]. As reported above, ELF5 
increases expression levels of STAT5. It was also reported 
that increas  ing STAT5 expression levels increases ELF5 
expression levels [59].
Th   e impact of STAT5, a known transcription factor, on 
the cell lies, at least in part, through regulation of gene 
expression. During lactation, STAT5 activation contri-
butes to the high expression levels of milk protein genes. 
STAT5 activation also has been linked to regulat  ing 
expression of the cell cycle control protein cyclin D1 both 
directly and indirectly [12,15,16,51,60-62] and expres  sion 
of receptor activator of nuclear factor-kappa-B ligand 
(RANKL) [62,63]. Signiﬁ   cantly, changes in STAT5 
expres  sion and activity can also modify the expression 
and activity of other STAT family members, most 
prominently STAT3 [60,64,65]. Th   ese changes in STAT3 
expression or activity then can modify gene expression 
patterns as a secondary eﬀ  ect.
In summary, STAT5 can be activated by diﬀ  erent and 
sometimes interacting signaling pathways in mammary 
epithelial cells. Th  e prolactin, EGF, estrogen, GH, and 
Figure 2. STAT5 can be activated by diverse and sometimes interacting signaling pathways in mammary epithelial cells. Prolactin (PRL) 
signaling networks dominate in STAT5 activation in normal mammary gland development with contributions from growth hormone (GH), insulin 
growth factor (IGF), estrogen, epidermal growth factor (EGF), and ErbB4 signaling. PRL and GH work predominantly through their respective 
receptors prolactin receptor (PR) and growth hormone receptor (GHR) through Janus kinase 2 (JAK2) and are key mediators of pregnancy-induced 
mammary gland development. Estrogen and EGF acting through respective receptors estrogen receptor-alpha (ERα) and EGF receptor (EGFR) 
initiate pubertal mammary gland development and contribute to pregnancy-induced development. They can interact through human cellular-Src 
(c-Src) pathways. Transforming growth factor-alpha (TGF-α) is the second ligand from the EGF family to be shown to infl  uence STAT5 activation 
levels in normal and cancer cells. IGF signaling through insulin growth factor-related receptors (IGFRs) may also include c-Src and, under some 
circumstances, JAK2 in both puberty- and pregnancy-induced development. The contribution of ErbB4 to STAT5 signaling is most prominent 
during lactation. In breast cancer, EGF and estrogen pathways acting through c-Src can drive proliferation and survival. JAK1 has been shown to 
increase PR/JAK2 activation in some settings. When the erythropoietin receptor (EPOR) is expressed in breast cancer cells and erythropoietin (EPO) 
is present, they can signal through JAK2 to STAT5 to promote resistance to trastuzumab therapy. ErbB4, v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 4, neuro/glioblastoma-derived oncogene homolog (avian); STAT5, signal transducer and activator of transcription 5.
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Page 3 of 14IGF pathways are well-established regulators of mam  mary 
epithelial cell behavior in both normal and malignant 
mammary epithelial cells. Th  e erythropoietin (EPO) 
path  way is a more recently recognized signaling pathway 
in malignant mammary epithelial cells. In addition to 
being regulated by activation through tyrosine phos-
phorylation, STAT5 activity can be regulated at the level 
of gene expression and a number of protein-protein 
interactions have been shown to inﬂ   uence its action. 
Downstream gene expression changes are thought to 
Figure 3. Signaling pathways and proteins that increase or decrease STAT5 signaling in normal mammary epithelial cells. Research to 
date has identifi  ed several factors that contribute to higher levels of STAT5 activation or, conversely, reduce activation levels in normal mammary 
epithelial cells. E74-like factor 5 (ets domain transcription factor) (ELF5) acts in the PRL/JAK2 signaling pathway to increase levels of STAT5 activation 
in normal mammary epithelial cells. Other signaling pathway components that increase STAT5 activation are EGF, ErbB2, transforming growth 
factor-alpha (TGF-α), estrogen acting with the progesterone pathway acting downstream, GH/JAK2, IGF, and c-Src. The TGF-β signaling pathway 
can decrease STAT5 activation levels. Cellular proteins that contribute to increased STAT5 activation include PI 3-kinase enhancer A (PIKE-A), serine/
threonine protein kinase Akt 1 (AKT-1), p21-activated kinase 1 (Pak1), the phosphotyrosine phosphatase Shp2, beta-integrin, and dystroglycan. 
Cellular proteins that have been shown to decrease STAT5 activation levels include caveolin-1 and suppressor of cytokine signaling 3 (SOCS-3). 
c-Src, human cellular-Src; EGF, epidermal growth factor; ErbB4, v-erb-b2 erythroblastic leukemia viral oncogene homolog 4, neuro/glioblastoma-
derived oncogene homolog (avian); GH, growth hormone; IGF, insulin growth factor; JAK2, Janus kinase 2; PRL, prolactin; Shp2, Src homology region 
2 domain-containing phosphatase-2; STAT5, signal transducer and activator of transcription 5.
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Page 4 of 14execute the diﬀ  erent actions of STAT5 on cellular diﬀ  er-
en  tiation, survival, and proliferation. Th   ese gene expres-
sion changes may include both direct eﬀ  ects  and 
secondary changes due to STAT5-mediated eﬀ  ects on 
other transcription factors, including other STAT family 
members such as STAT3.
The STAT5 signaling node in normal mammary 
gland development
STAT5 plays a critical role in the development and diﬀ  er-
en  tiation of the normal mammary gland toward lacta-
tional competence [7]. It is essential for the generation of 
luminal progenitor cells that diﬀ  erentiate into alveolar 
Figure 4. Signaling pathways and proteins that can increase or decrease STAT5 signaling in breast cancer cells. Research to date has 
identifi  ed several factors that can contribute to higher levels of STAT5 activation or, conversely, reduce activation levels in breast cancer cells. As 
in normal mammary epithelial cells, PRL/JAK2, c-Src, EGF/EGFR, ErbB4, TGF-α, estrogen and progesterone, and IGF pathways can increase STAT5 
activation. In breast cancer cells, EPO/EPOR and HOXA1 also have been shown to increase STAT5 signaling. Two cellular proteins shown to increase 
STAT5 activation in breast cancer cells are breast tumor kinase (Brk) and transcription factor proto-oncogene v-Myb myeloblastosis viral oncogene 
homolog (avian) (c-Myb). As in normal mammary epithelial cells, caveolin-1 and SOCS-3 can downregulate STAT5 activation; however, in breast 
cancer cells, PTPN9 (protein tyrosine phosphatase, non-receptor type 9) also has been shown to downregulate STAT5 signaling. c-Src, human 
cellular-Src; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; EPO, erythropoietin; EPOR, erythropoietin receptor; ErbB4, 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 4, neuro/glioblastoma-derived oncogene homolog (avian); HOXA1, homeobox A1; IGF, 
insulin growth factor; JAK2, Janus kinase 2; PRL, prolactin; SOCS-3, suppressor of cytokine signaling 3; STAT5, signal transducer and activator of 
transcription 5; TGF-α, transforming growth factor-alpha.
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Page 5 of 14cells, although it is not required for the appearance of 
mammary ductal cells or the production of mammary 
stem cells [21,66]. STAT5A is the more prominent STAT 
family member expressed in the mammary gland. During 
pubertal development, its absence results in defects in 
secondary ductal and side branching [62] and delayed 
diﬀ  er  entiation of terminal end buds when coupled with 
mammary epithelial cell-targeted ERα overexpression 
[43]. During pregnancy, it plays an essential role in 
mammary gland lactational development and in diﬀ  er-
entiation and expression of milk protein genes [6]. 
However, in its absence, STAT5B can be upregulated, 
especially with serial pregnancies, and substitute for 
STAT5A [9]. STAT5 activation is downregulated at the 
onset of post-lactational involution [8].
To date, a larger number of signaling pathways and 
proteins have been identiﬁ   ed as contributing to the 
activation of STAT5 during normal development and 
lacta tional  diﬀ   erentiation than have been shown to 
downregulate this pathway (Figure  3). Th  is may be 
because inadequate levels of STAT5 activation result in 
the readily apparent defect of insuﬃ   cient milk production 
whereas increased STAT5 activation produces the less 
obvious developmental abnormality of precocious alveolar 
diﬀ  erentiation during pregnancy and, only later, hyper-
plasia and cancer [55,60,66,67]. Estrogen signaling and 
progesterone signaling contribute to regulating normal 
levels of STAT5 expression in the non-pregnant gland 
[39,68]. Th  e transcription factor ELF5 is reported to lie 
functionally upstream of STAT5 and downstream of 
prolactin [69]. Its absence compromises STAT5 expres-
sion levels and activity in mammary epithelial cells and 
results in loss of normal lobuloalveolar development [42]. 
While during normal development STAT5 is activated 
primarily by PRL signaling pathways, EGF and GH 
signal  ing pathways can also contribute [32,70]. ErbB4 has 
a deﬁ   ned role in mediating STAT5 activation during 
lactation [35]. Activation of EGF signaling pathways by 
the introduction of expression of transforming growth 
factor-alpha (TGFα) through a mammary epithelial cell-
targeted transgene can interrupt the downregulation of 
STAT5 activation and promote mammary epithelial cell 
survival during involution [70]. PIKE-A, active in AKT 
signaling, associates with STAT5 and PRLR and its 
absence results in impaired mammary epithelial cell 
proliferation and lactation [51]. Pak1 interacts with and 
serine phosphorylates STAT5 and interruption of the 
normal function of Pak1 reduces lobuloalveolar growth 
and milk produc  tion [18]. Ablation of Akt1, but not Akt2 
or  Akt3, interferes with STAT5 activation in late 
pregnancy and lactation [52,71]. Loss of one copy of the 
Akt2 gene coupled with ablation of Akt1 results in the 
loss of STAT5 activation associated with increased 
expression of caveolin-1 and SOCS-2, negative regulators 
of STAT5 [52]. Th  e phosphotyrosine phosphatase Shp2 
reciprocally modulates STAT5 and STAT3 activation in 
the mammary epithelium. Deletion of this molecule 
results in impaired STAT5 activation but slightly 
increased STAT3 activity [72]. Ablation of Src in normal 
mammary epithelial cells impairs STAT5 activation 
through the downregulation of PRLR [27]. Finally, 
structural molecules outside the mammary epithelial cell, 
including beta-integrin [73,74] and the basement 
membrane receptor dystroglycan [75], also play a part in 
establishing the normal levels of STAT5 activation 
required for lactational diﬀ   erentiation. Loss of 
dystroglycan interrupts mammary gland outgrowth and 
lactation competency that is correlated with decreased 
STAT5 activity. Negative regulators of STAT5 include 
TGF-β, which has been reported to downregulate prolactin-
induced JAK/STAT5 activation [76,77]. If caveolin-1 is 
absent, STAT5 activation is increased with subsequent 
development of mammary hyper  plasia and cancer [55].
Candidate downstream mediators of STAT5 activity 
during normal development include RANKL [62,63] and 
cyclin D1 [51,62]. STAT5 also has the ability to bind to 
consensus sequences within the Akt1 locus which deﬁ  ne 
a unique promoter active only in mammary epithelial 
cells [61].
The STAT5 signaling node in normal mammary 
stem cells and cancer progenitor cells
STAT5 has a well-deﬁ  ned role in the regulation of stem 
and progenitor cells in hematopoietic systems [78-80]. 
Studies in the mammary gland reveal a role for STAT5 in 
the development of the mammary epithelial alveolar cell 
lineage [21,59,66] (Figure 5). Th   e cellular repertoire of the 
mammary gland is generated by growth and diﬀ  eren-
tiation from a stem cell component coordinated by 
hormones and cytokines. Mammary stem cells have a 
distinctive capacity for self-renewal and give rise to the 
three principal lineages that encompass the normal 
lobuloalveolar structure of the adult mammary gland: 
myoepithelial cells that form the basal layer of ducts and 
alveoli, ductal epithelial cells lining the lumen of ducts, 
and alveolar epithelial cells that have the capacity to 
synthesize milk proteins in large quantities [81]. In the 
absence of STAT5, mammary alveologenesis is abrogated 
through a reduction in the mammary luminal progenitor 
cell population [21,66]. STAT5 is required not only for 
proliferation and survival of alveolar cells but also for the 
generation of alveolar progenitor cells from stem cells. 
Importantly, the defect is limited to this lineage and loss 
of STAT5 does not aﬀ  ect the underlying mammary stem 
cell population. Ductal cells do develop in the absence of 
STAT5 [21], but while primary ductal extension is 
normal, impaired side branching is reported [62]. Consis-
tent with the impact of STAT5 loss, gain of a constitu  tively 
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Page 6 of 14active STAT5A causes otherwise relatively quiescent 
ductal epithelial cells in virgin mice to undergo rapid 
expansion and develop into alveolar-like structures [59]. 
Consistent with the position of ELF5 as a STAT5 
regulator, gain of ELF5 induces diﬀ  erentiation of luminal 
progenitor cells into alveolar cells [69]. In a reciprocal 
fashion, gain of STAT5 is associated with increased ELF5 
expression levels [59], indicating that the two factors 
have a bi  directional interaction.
Whether or not STAT5 plays a role in cancer progenitor 
cell pathophysiology is under investigation. Gain-of-
function experiments using a Stat5 variant, cS5-F, in 
which serine 710 is mutated, demon  strate that STAT5 
overexpression in mouse models can lead to the 
development of ER+/PR+ adenocarcinomas harboring a 
small fraction of CD44+ cells that are postulated to 
represent a population of cancer progenitor cells [66].
The STAT5 signaling node in mouse models of 
breast cancer
Th  e impact of increasing or decreasing the STAT5 
activity on mammary cancer initiation, promotion, and 
progression has been investigated from a mechanistic 
perspective by using genetically engineered mouse models 
(Figure 6). Mammary epithelial cell-targeted over  expres-
sion of genetically engineered STAT5 variants is suﬃ   cient 
for initiation, promotion, and progression along a cancer 
pathway, resulting in mostly well-diﬀ  erentiated adeno-
carcinomas, sometimes exhibiting a papillary archi-
tecture, and a low percentage of undiﬀ  erentiated carci-
nomas [60,66,67]. Loss of caveolin-1 in mammary 
epithelial cells induces hyperactivation of STAT5A 
signal  ing, leading to the development of mammary 
hyperplasias and well-diﬀ  erentiated cancers [55]. STAT5 
also contri  butes to mammary cancer progression 
initiated by mammary epithelial cell-targeted over-
expression of PRL [23], simian virus 40 T antigen (TAg) 
[82], and TGF-α [70]. Signiﬁ  cantly, JAK2 is required to 
initiate mammary cancer development by PRL 
overexpression but is dispensable for cancer cell survival 
and proliferation [83], exerting a ‘hit and run’ eﬀ  ect in 
mammary carcinogenesis. Similarly, loss of STAT5A 
reduces the prevalence of ERα-initiated mammary 
preneoplasia but does not prevent the development of 
invasive cancer [43]. Upregulation of growth factors 
known to contribute to mammary carcino  genesis, 
including ErbB2 [43,83] and cyclin D1 [43], is found in 
the cancers that develop in the absence of either JAK2 or 
STAT5a and that may be responsible for sustaining the 
cancer cell growth.
The STAT5 signaling node in benign human breast 
disease and cancer
Stat5 is expressed in a high proportion of human breast 
cancers [84,85]. Activation of STAT5 in breast cancers is 
statistically associated with higher levels of diﬀ  erentiation 
[85] and a better prognosis [84] and response to endo-
crine therapy when co-expressed with ERα [86]. Consis-
tent with these results, higher expression levels of STAT5 
target genes such as IGF-1 and SOCS-2 also correlate 
with a better prognosis [57]. Decreased expres  sion levels 
of STAT5A are found more frequently in high-grade 
breast cancers as compared with normal breast tissue or 
Figure 5. STAT5 is required for diff  erentiation of luminal 
progenitor cells into alveolar cells. STAT5 activation mediates 
alveolar cell fate commitment and proliferation that leads to 
lactational diff  erentiation. Mammary stem cells give rise to progenitor 
cells that diff  erentiate into ductal or luminal progenitor cells. ELF5 
induces diff  erentiation of luminal progenitor cells into alveolar 
cells downstream of prolactin signaling. Cell types illustrated in 
pink exhibit STAT5 activation. ELF5, E74-like factor 5 (ets domain 
transcription factor); PRL, prolactin; STAT5, signal transducer and 
activator of transcription 5.
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Page 7 of 14ductal carcinoma in situ lesions. Th   e absence of activated 
STAT5 correlates with a higher probability of not 
responding to endocrine therapy [87]. Th   ese lower levels 
of STAT5A are associated with increased expression 
levels of proto-oncogene B-cell chronic lymphocytic 
leukemia/lymphoma 6 (BCL6), a transcriptional repressor 
that recognizes similar DNA target sequences [88]. 
Interestingly, a PRLR gain-of-function mutant resulting 
in increased STAT5 signaling is associated with the 
presence of multiple benign breast ﬁ  broadenomas [89].
A correlation between increased STAT5 expression and 
cellular transformation has also been shown in mammary 
epithelial cells in which activation levels of STAT5 are 
increased. Overexpression of the homeobox A1 (HOXA1) 
gene in these cells induces increased STAT5B expression 
that is associated with increased cell prolifera  tion, 
survival, and oncogenic transformation [90]. Interest-
ingly, STAT3, but not STAT5A, is simultaneously induced 
by HOXA1, and downregulation of either STAT5B or 
STAT3 is suﬃ   cient to abrogate the phenotype. STAT5 
Figure 6. Increased STAT5 initiates cancer and decreased STAT5 diminishes cancer promotion in genetically engineered mouse models. 
Increased levels of STAT5 expression and/or activation either directly by transgene-mediated STAT5 overexpression or indirectly through genetically 
engineered loss of caveolin-1 leads to initiation, promotion, and progression to mammary cancer. Decreased levels of STAT5 expression reduce 
cancer promotion initiated by transgene-mediated overexpression of prolactin, transforming growth factor-alpha (TGF-α), and estrogen receptor-
alpha (ERα) as well as mammary-targeted simian virus 40 T antigen. STAT5, signal transducer and activator of transcription 5.
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Page 8 of 14activation mediated by artiﬁ  cial induction of the EPO 
receptor into the benign non-invasive rat mammary cell 
line, Rama 37, leads to increased colony formation, 
invasion, migration, and changes in adhesion associated 
with increased extracellular signal-regulated kinase 
(ERK) and AKT [91].
Th  e observations in human breast cells coupled with 
the pathophysiological studies in mouse models raise 
interesting questions about the role of STAT5 in human 
breast cancer. It would appear that, when the mechanistic 
mouse studies are taken together with the descriptive 
human studies, STAT5 activation is deﬁ  nitively  com-
patible with cancer cell growth and increased levels of 
STAT5 activation may contribute to cancer progression. 
However, the cancers exhibiting STAT5 expression are 
more diﬀ   erentiated and statistically more likely to 
respond to endocrine therapy and perhaps are therefore 
associated with a better prognosis. Experiments in human 
breast cancer cell lines have demonstrated that this may 
be because STAT5 is able to maintain some of its ability 
to promote cellular diﬀ  erentiation in cancer cells, as it 
does during normal development. Th  ese studies have 
identiﬁ  ed  speciﬁ   c cellular behaviors and downstream 
genes that can be inﬂ   uenced by changes in STAT5 
expression and activation (Figure 7).
In some experimental systems, STAT5 has been shown 
to contribute to diﬀ  erentiation of breast cancer cells and 
this contribution is reminiscent of its role in normal 
mammary gland development. In BT-20 and T47D breast 
cancer cells, the combination of STAT5 and Jak2 over-
expression induces a mesenchymal-to-epithelial transi-
tion when the cells are grown in a three-dimensional 
matrigel assay. Th   e cells shift to a luminal epithelial cell 
phenotype and become less invasive [92]. Paralleling 
these results, diﬀ   erentiation as measured in a three-
dimensional culture assay is impaired when kinase-dead 
ErbB4 mutants that reduce STAT5 activation levels are 
placed into MDA-MB-468 breast cancer cells [33]. 
STAT5 has been found to attenuate prolactin signaling to 
activating protein-1 (AP-1), perhaps through direct bind-
ing. Loss of STAT5 in T47D cells increases prolactin-
induced AP-1 signaling, matrix metalloproteinase-2, and 
invasive behavior [93], and forced increased expression 
levels of STAT5 can inhibit motility of MCF-7 and T47D 
cells [13].
In other experiments, STAT5 activation in cancer cells 
enhances behaviors conventionally associated with ad-
vanced malignancy. Th   e same experiments that demon-
strated that forced expression of STAT5 in MCF-7 and 
T47D cells suppresses cell motility showed that it 
enhanced cell survival and anchorage-independent growth 
[13]. In MDA-MB-231 and BT-549 cells, knockdown of 
STAT5B can inhibit beta-1-integrin-mediated cell 
migration [14].
BCL6 represents a gene whose upregulation is asso-
ciated with loss of diﬀ  erentiation of breast cancer cells 
when STAT5 expression is reduced [88]. STAT5A, but 
not STAT5B, is able to repress BCL6 expression through 
a prolactin-induced mechanism. Whereas STAT5 
represses BCL6 expression, STAT3 increases BCL6 
expression. However, STAT5 is dominant over its related 
family member STAT3 in regulating BCL6 expression 
levels in T-47D and SK-BR-3 cells [65]. Moreover, in 
MDA-MB-468 cells, the same authors demonstrated that 
simul  taneous STAT5 and STAT3 activation resulted in 
decreased proliferation and increased sensitivity to 
paclitaxel and vinorelbine as compared with cells with 
STAT3 activation alone.
STAT5A signaling in breast cancer cells can be 
modiﬁ  ed by interactions with c-Myb [53] and Brk [54]. c-
Myb and STAT5A associate in a PRL-inducible manner 
in T47D and MCF7 breast cancer cells, stimulate expres-
sion of STAT5A downstream genes, and are associated 
with increased PRL-induced cell proliferation. Brk can 
phos  phorylate STAT5 through a mechanism involving 
signal-transducing adaptor protein 2 (STAP-2). Knock-
downs of STAT5B, Brk, and STAP-2 equivalently reduce 
prolifera  tion of T47D breast cancer cells.
Downstream STAT5 genes, including SOCS-3, can 
feedback to regulate STAT5 activity in breast cancer cell 
lines. For example, overexpression of SOCS-3 in T47D 
cells reduces PRL-induced STAT5 phosphorylation and 
this is correlated with decreased cell proliferation [94]. 
Expression of PTPN9 (protein tyrosine phosphatase, 
non-receptor type 9) is reported to reduce STAT5 activa-
tion coincident with growth inhibition as measured in 
soft agar assays by using SKBR3 and MDA-MB-231 
breast cancer cell lines, perhaps (in whole or in part) 
through regulation of ErbB2 and EGFR phosphorylation 
[95].
STAT5 regulates expression of genes that promote cell 
survival and proliferation in breast cancer cells. For 
example, STAT5 can induce expression of heat shock 
protein 90-A (HSP90A), a protein that can promote 
cancer cell survival. In SKBR3 breast cancer cells, PRL 
increases HSP90A, and STAT5B activates the HSP90A 
promoter [96]. IGF was found to lie downstream of 
STAT5 in breast cancers, including ERα-negative breast 
cancer cells [12,57]. Cyclin D1 also lies downstream of 
STAT5 in breast cancers [12,15,16,38]. It should be 
understood that, while HSP90A, IGF, and cyclin D1 lie 
downstream of STAT5 activation, their expression 
patterns, activity, and impact on cellular growth can be 
modiﬁ  ed by other cellular factors and signaling molecules 
expressed in breast cancer cells [36,97-99].
STAT5 activation has been correlated with response to 
endocrine therapy, although currently there is a discon-
nection between available in vivo and in vitro data. 
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demonstrate a positive correlation between STAT5 
activa  tion and response to endocrine therapy [86,87], 
whereas constitutive activation of STAT5B in T47D 
Figure 7. STAT5 expression in human breast cancer is generally associated with increased diff  erentiation. In human breast cancer tissue, 
STAT5 expression has been reproducibly associated with increased diff  erentiation and a better prognosis and response to endocrine therapy. 
Experiments that alter STAT5 expression levels in breast cancer cell lines revealed a link between the presence of STAT5 and increased diff  erentiation 
in BT-20, T47D, and MDA-MB-468 breast cancer cell lines. Increased cell motility, invasiveness, and migration are behaviors that can be found in 
association with decreased diff  erentiation. In MCF-7 andT47D cells lines, STAT5 inhibits motility, and in the T47D cell line loss of STAT5 increases 
invasiveness and this is consistent with the correlation between STAT5 and increased diff  erentiation. However, in MDA-MB-231 and BT-549, loss of 
STAT5 actually inhibits migration. Increased sensitivity to therapy is considered a good prognostic sign, and in the MDA-MB-468 cell line, STAT5 is 
correlated with increased sensitivity to paclitaxel and vinorelbine. However, in SKBR3, MCF-7, and T47D cell lines, experiments have correlated the 
presence of STAT5 with increased cell survival and, in T47D cells, resistance to tamoxifen and, in SKBR3 cells, a decreased response to trastuzumab. 
In SKBR3 and MD-MBA-231 cells, loss of STAT5 is actually correlated with growth inhibition. These sometimes consistent and sometimes confl  icting 
results in diff  erent breast cancer cell lines indicate that the relative impact of STAT5 on cell diff  erentiation, survival, and proliferation can be cell line-
specifi  c. BCL6 gene expression and activating protein-1 (AP-1) signaling are reduced by increased STAT5 signaling and increased by reduced STAT5 
signaling. Identifi  ed downstream STAT5 genes in breast cancer cells include heat shock protein 90-A (HSP90A), insulin growth factor (IGF), and cyclin 
D1. BCL6, proto-oncogene B-cell chronic lymphocytic leukemia/lymphoma 6; STAT5, signal transducer and activator of transcription 5.
HUMAN BREAST CANCER
Increased STAT5 Increased STAT5 Decreased STAT5 Decreased STAT5
Correlated With: Correlated With: Correlated With: Correlated With:
Increased Differentiation Poor Clinical Outcome 
Cancer Cell Line Behavior Cancer Cell Line Behavior
Better Response to Endocrine Therapy Worse Response to Endocrine Therapy 
Cancer Cell Line Behavior Cancer Cell Line Behavior
BT-20 Mesenchymal to epithelial transition
T47D Mesenchymal to epithelial transition
MCF-7 inhibits motility
T47D inhibits mobility
SKBR3 enhanced survival
MCF-7 enhanced survival
T47D enhanced survival
f
MDA-MB-468 impaired
differentiation
SKBR3 growth inhibition
MDA-MB-231 growth inhibition
T47D increased invasiveness
MDA-MB-231 inhibits migration
BT-549 inhibits migration
T47D increased tamoxifen resistance
SKBR3 decreased response to trastuzumab
MDA-MB-468 increased sensitivity to paclitaxel 
and vinorelbine 
Downstream Targets Downstream Targets Downstream Targets Downstream Targets
Increased BCL6
Increased AP-1 signaling
Reduced BCL6
Reduced AP-1 signaling 
Increased HSP90$
Increased IGF
Increased Cyclin D1
Furth et al. Breast Cancer Research 2011, 13:220 
http://breast-cancer-research.com/content/13/5/220
Page 10 of 14breast cancer cells is reported to induce tamoxifen resis-
tance [16].
Development of a unifying hypothesis of STAT5 
action and future directions
An examination of the diﬀ  erent results from both normal 
and malignant mammary epithelial cells, in mice and in 
women, reveals some commonalities in the diﬀ  erent 
experimental systems employed. One is the mechanistic 
impact of STAT5 activation on diﬀ   erentiation in the 
mouse and cell line studies coupled with its correlation 
with diﬀ  erentiation in the human breast cancer tissue 
studies. In both normal and malignant mammary epi-
thelial cells, STAT5 is positively associated with diﬀ  er-
entiation. Similarly, STAT5 contributes to improving cell 
survival and increasing cell proliferation in both normal 
and malignant cells. However, cellular diﬀ  erentiation 
appears to be the most frequently altered feature found 
when STAT5 activation or expression levels are high and 
therefore one signiﬁ  cant factor in a unifying hypothesis 
of STAT5 action.
A second feature of a unifying hypothesis of STAT5 
action is that, although many of the signaling pathways 
that activate STAT5 and cellular proteins that interact 
with it are similar in normal and malignant mammary 
epithelial cells, diﬀ  erences in the degree to which the 
diﬀ   erent components contribute exist. In normal 
mammary epithelial cells, the PRL/PRLR/JAK2 pathway 
dominates, whereas in cancer cells signiﬁ  cant  STAT5 
activation can occur through EGF and c-Src with contri-
butions from estrogen and progesterone signaling 
pathways and even the EPO pathway. Another diﬀ  erence 
between normal and malignant mammary epithelial cells 
lies in the relative contributions of STAT5A and STAT5B. 
In normal mammary epithelial cells, STAT5A is the 
dominant actor, whereas in malignant mammary 
epithelial cells, STAT5B can be the more signiﬁ  cant 
contributor.
A third feature for a unifying hypothesis for STAT5 
action is its ability to contribute to cancer initiation, 
promotion, and progression and at the same time be a 
critical component of normal mammary gland develop-
ment. In this respect, it shares the challenges of other 
growth factor pathways involved in normal mammary 
gland development, including estrogen, progesterone, 
EGF, and IGF pathways. When properly regulated, these 
pathways mediate normal growth, cellular proliferation, 
and diﬀ   erentiation but can contribute to neoplastic 
transition and unrestrained cellular proliferation when 
their activation becomes unbalanced or associated with 
oncogenic changes in the cell or both.
Finally, the contribution of STAT5 to the speciﬁ  cation 
of progenitor cells has to be considered in any unifying 
hypothesis of STAT5 action. Here, there is clear 
deﬁ  nition of its role in specifying alveolar cell lineage 
diﬀ   erentiation during normal development, but its 
contribution to cancer progenitor cell biology is less well 
deﬁ  ned. One can speculate that it may ‘specify’ a type of 
breast cancer progenitor cell, perhaps a more diﬀ  eren-
tiated one that shares morphological or biological 
features with alveolar cells. In support of this conjecture, 
STAT5 overexpression in mice is associated with the 
develop  ment of papillary adenocarcinomas, a more 
diﬀ   er  entiated histological type that is not commonly 
found in genetically engineered mouse models of cancer.
At present, a unifying hypothesis of STAT5 action in 
mammary epithelial cells would include the following 
statements. STAT5 is a protein with dominant eﬀ  ects on 
cellular diﬀ  erentiation and lineage speciﬁ  cation that lead 
to proliferation and survival of speciﬁ  c mammary cell 
types. It has the ability to contribute to growth and 
survival in both normal and cancer cells. Well-established 
mammary cellular growth factors and hormones from 
outside the cell acting through their receptors are the 
most frequent activators of STAT5. Th   e degree to which 
the diﬀ  erent pathways contribute to STAT5 activation 
varies between normal and malignant mammary cells 
and between diﬀ  erent types of breast cancer cells.
Future directions for study build upon this broad 
hypothesis. While the role of STAT5 in lineage speciﬁ  -
cation of normal mammary epithelial cells appears clear, 
it is important to know whether STAT5 also can specify 
speciﬁ  c lineages of breast cancers. Human breast cancer 
is not a unitary disease but rather is composed of 
diﬀ   erent types with some unique pathological and 
molecular features. One hope is that we can build upon 
our previous success with targeted endocrine and ErbB2-
targeted therapy to develop a more eﬀ  ective treatment 
that is more speciﬁ   cally designed for speciﬁ  c  breast 
cancer types. If STAT5 were to specify a particular type 
of breast cancer, this knowledge could be used for better 
treatment and prevention. Related to this is the possibility 
that the activity level of STAT5 could be used as a marker 
to help select individuals who might respond better to 
particular therapies or indicate women who might 
require closer follow-up or a diﬀ  erent approach because 
their risk of non-response would be increased. Th  e  most 
immediate need for additional research in this area might 
be in regard to endocrine therapy and to the combination 
of trastuzumab with EPO-type drugs. In regard to endo-
crine therapy, we need to know why activation of STAT5 
is correlated with a higher response rate. Is this a simple 
correlation with ERα status and higher diﬀ  erentiation 
levels, or does STAT5 activation play a mechanistic role 
in improving the response? Th  e fact that an interaction 
between EPO and trastuzumab has been identiﬁ  ed raises 
the possibility that other competing interactions between 
signaling pathways may occur and should be sought. 
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embedded within a network of cellular signaling path-
ways. Future studies will have to try a more global 
analysis of this network as opposed to focusing on a 
limited number of readouts. Th  is is true for all three 
major types of experiments that examine STAT5 action: 
mouse model studies, tissue culture cell studies, and 
human tissue studies. In each of these approaches, 
investi  gators will need to examine not only STAT5 activa-
tion but also associated family members and the constel-
la  tion of interacting proteins and signaling path  ways that 
impact STAT5. Finally, STAT5 is described as a trans-
cription factor. Whereas some of its downstream genes 
are characterized, the transcriptional networks that lead 
to the diﬀ  erent cellular behaviors associated with STAT5 
activation are not fully deﬁ  ned. Further deﬁ  nition of the 
genetic networks lying downstream of STAT5 remains a 
highly relevant research goal.
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